Introduction
Brain tumor related epilepsy is an important aspect of the burden of disease for patients with glioma and often pose a therapeutic challenge. The risk of epileptic seizures is 70-90% for patients with low grade glioma (LGG) and 30-60% for patients with high grade glioma (HGG) [1] [2] [3] [4] [5] . In this study, we explored status epilepticus (SE) in a prospective patient database with glioma and epilepsy. SE is a life-threatening medical emergency in which seizure activity continues for a prolonged period of time, or where seizures recur before full clinical recovery from the preceding seizure [6, 7] . The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have proposed a new definition of SE: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures. It is a condition which can have long-term consequences, including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures [8] . SE is often operationally defined as 5 min of continuous seizure or two or more discrete seizures between which there is incomplete recovery of consciousness [9] . If inadequately treated and lasting beyond 30 min, which is the older definition of SE, this condition can result in permanent pathophysiological changes [6, 10] . Thus, SE requires immediate treatment, often in an intensive care unit (ICU). Brain tumor is the cause of SE in 3-12% of adult cases [11] [12] [13] [14] . Previous studies on SE in glioma patients [15] [16] [17] [18] have been retrospective, of small sample size and including tumors of various histologies.
The aim of our study was to investigate SE in a prospective material of adult patients with verified glioma. We investigated the relationship of SE to tumor grading, seizure semiology, trigger factors and treatment response, in addition to recurrence and outcome. Our research is important to gain a better understanding of this challenging epileptic condition in a patient group with complicating underlying tumor.
Material and methods
Patients with SE and glioma were identified from a prospective clinical study of adult patients with verified glioma WHO grade II-IV and one or more epileptic seizures during the course of disease. The study has been ongoing since 2008 with inclusion of all eligible patients at the only two neurological departments in two counties of western Norway (Haukeland University Hospital in Bergen, Hordaland County and Central Hospital, Sogn and Fjordane County) since 2009. These two counties have a population of 620,527 (Statistics Norway 01.01.15). The glioma patients are followed clinically and radiologically from their first seizure until death. Neurological, oncological and paraclinical data are collected every 6 months and at other admittances to the hospitals. By 10.12.2014, 20 patients had been registered with SE, once or on several occasions. These 20 glioma patients had in total 31 SE. We adhered to the old definition of SE as seizures lasting beyond 30 min, as this is regarded as the threshold for neurological damage. We evaluated the medical records, prehospital information, blood analyses, cerebral CT and MRI, EEG and follow-up data of all patients. For descriptive purposes, all 31 status episodes were included. In patients with multiple SE episodes, only the first episode was included in the statistical analyses, to avoid the bias of repeated measurements in one subject. The study was approved by Regional Committees for Medical Research Ethics (REK 2008/ 11243) and all patients gave a written consent.
Theory/calculation

Definitions
SE was defined as either 30 min of continuous seizure activity or two or more sequential seizures without recovery of full consciousness between the seizures [19] . Although the definition was recently modified, we adhered to this version which is often used in evaluating prognosis and has been used throughout the study period [8, 20] . Seizures were classified as focal SE without consciousness impairment, focal SE with consciousness impairment or secondary generalized SE. Refractory status epilepticus (RSE) was defined as SE unresponsive to two AEDs and/or requiring anesthetic agents for seizure control [21, 22] . If the patient was treated with two different benzodiazepines as first line treatment, this was considered as the same AED.
The patients were grouped according to histological diagnosis at onset of disease, or, in case of malignant transformation, according to the most recent histological diagnosis. The LGG group includes astrocytoma and oligodendroglioma of WHO grade II. HGG includes anaplastic astrocytoma (WHO grade III) and glioblastoma (GBM) (WHO grade IV) [23] . SE was categorized as onset symptom if the seizure unfolded within 30 days prior to glioma diagnosis. Progression was defined as radiographic changes and clinical signs consistent with tumor progression within 30 days of the SE. Mortality was defined as death within 30 days after the SE. Sequela was defined as a neurological deficit acquired during the SE and documented in the medical record as persistent at time of discharge, or at the next control appointment at the hospital. Mild sequelae were defined as transient neurological deficits lasting less than 1 month. Moderate sequelae were defined as neurological deficits that were still present more than 1 month after SE. Major sequelae were defined as permanent neurological deficits which severely impaired functional ability. Background variables were compared using cross-tables with Fisher's exact test of independence. Two-sided P values 0.05 were interpreted as statistically significant dependence of variables.
Statistical methods
Statistical analyses were carried out in IBM SPSS
Results
Patient and tumor characteristics
We identified 31 SE in 20 patients (Table 1) . Five patients had LGG and 15 had HGG. Two of the HGG were transformed from previous LGG. The glioma was localized in the left hemisphere in 60%. Four tumors had a frontal location, ten were localized in the parietal lobe or frontoparietal region, four were temporal lobe tumors, one was occipital and one multilobal.
SE characteristics
The SE was secondary generalized in 15/31 (48%), focal with consciousness impairment in eight (26%) and focal without consciousness impairment in eight (26%) (Fig. 1) . Repeated SE was seen in seven of the 20 patients. Six of them had HGG, including two patients with four SE each. The single LGG patient had oligodendroglioma with SE as onset symptom and a second SE several years later, at a time with no AED use.
The duration of SE varied from 30 min to 4 days ( Table 2 ). The focal seizures more often persisted longer than 5 h than the secondary generalized seizures (P = 0.01). In patients where SE led to initial glioma diagnosis (seven SE) or diagnosis of progression (eight SE), we regarded the tumor as the main SE trigger factor. In the other 16 SE, the tumor was stable and other possible trigger factors were identified, as ongoing radiotherapy with or without concomitant chemotherapy (four), intercurrent disease (one) or changes in AED regimen (two). Most SE occurred in a setting of well-controlled epilepsy with no or few seizures the last month (Table 2 ). Four SE occurred in patients with no prophylactic AED treatment, in addition to the seven SE which heralded glioma diagnosis. Of the 20 SE in patients taking prophylactic AEDs, only six were during polytherapy. Two patients had serum AED levels below and one patient above the reference areas at SE.
First line treatment was sufficient to terminate the seizures in 15/31 SE (48%) and second line treatment was needed in 7/31 (23%) ( Table 2 ). Eight cases were RSE; additional levetiracetam and/or valproate were needed in six SE and general anesthesia with propofol in two. Of the recurrent SE, four were treated successfully with first line treatment, three needed second line treatment and four were RSE. Considering only the first SE in every patient, 16/20 (80%) responded to first or second line treatment. None of the first SE episodes required general anesthesia. SE in patients with tumor progression was not proven to be statistically significant more treatment refractory (P = 1.00).
Outcome after SE
Sequelae in terms of new neurological deficits were present after 6/20 first SE (30%), one patient with tumor progression and five patients without tumor progression. Mild sequelae were aphasia and diminished hand motility. Moderate sequelae were exacerbation of hemiparesis, aphasia and impaired balance. Major sequelae were severe exacerbation of hemiparesis, dysarthria and impaired consciousness. Patients with SE and tumor progression had a worse outcome after SE (major sequelae or death within 3 months after SE) (P = 0.01).
At the end of this study, 16 patients were dead (Table 3) . Mean and median time from glioma diagnosis to death were 28.5 months and 20 months (minimum 3, maximum 152). Follow-up from glioma diagnosis to end of study for the four survivors were 12-52 months. No patient died during SE or earlier than 3 weeks after SE. Six patients died within 3 months after SE, of which two were de novo GBM with recurrent SE. One of these patients died 2 months after her second SE and the other patient died 21 days after his fourth SE. Death within 3 months occurred in 0% of LGG and 40% of HGG. Additionally, two of the six patients died within 30 days of SE; one had transformed GBM and one anaplastic astrocytoma, which gave a 30 days' mortality rate of 0% for LGG and 20% for HGG.
Discussion
The majority of SE occurred in HGG patients. This is surprising as the survival time is shorter in HGG and seizures are more frequent in LGG than in HGG. Advances in oncological therapy may affect the prevalence of seizures in glioma. Temozolomide has prolonged the survival time for GBM patients and may thus increase the incidence of epilepsy in this group. The pathophysiology of epilepsy in LGG and HGG is different, as the slow growth in
LGG allows for development of functional changes whereas the rapid growth in HGG leads to distortion of cortical tissue and edema [24, 25] . Even though single or recurrent seizures are more common in LGG, the risk of tumor associated SE appears to be directly proportional to tumor grade [26] . HGG is fivefold as common as LGG in Europe [27] but as epilepsy was the major inclusion criterion, LGG constitutes as many as half of the patients in our database. Nevertheless, we found that 75% of first SE was in HGG, compared to 44% in a previous study [16] . Rosati et al. found a lower frequency of epilepsy in de novo GBM than in secondary GBM, supporting the hypothesis that the mechanisms of seizure in slow-growing and fast-growing tumors are different [24] . Aggressive tumors with insufficient blood supply cause intratumoral hypoxia and acidosis that may extend to surrounding tissue and cause glial swelling and damage leading to risk of seizures [28] . Two of our patients had secondary GBM. Other factors may also explain the higher frequency of SE in HGG. Chemotherapy may affect AED levels [29] , and although seizure control usually improves by radiotherapy, some patients have seizures due to acute radiation encephalopathy. The four patients with SE related to oncological treatment were all GBM. Corticosteroids decrease susceptibility to seizures in laboratory studies [30] , and are used liberally as anti-edema therapy in HGG. Dose tapering may increase susceptibility to seizures, also due to increased edema, although no studies investigate this issue. Most HGG in our study were treated with dexamethasone. In half of the SE, the semiology was secondary generalized seizures. Most previous studies of SE in glioma have not defined seizure type [18] or only included particular seizure types [15, 17] , thus making a general comparison of semiology with these studies challenging. Brain tumors have earlier been regarded as having the propensity to cause focal SE rather than secondary generalized SE [31] . However, the majority of brain tumor patients with SE in an Italian study [16] also suffered secondary generalized SE, similar to our results. For SE in general, secondary generalized seizures are reported to be observed in 19-66% of patients [32] . The recurrence rate was 35%, which is roughly comparable with a recent estimate not limited to tumor patients of 32% [33] .
The glioma was most often located in the parietal lobe. Parietal tumors are easier to operate, with improved survival and thereby longer possibility for developing SE. Another reason for our finding can be that the risk of epileptic seizures is substantial in tumors of the parietal lobes [34, 35] .
Four times as many males than females were affected by SE, which cannot be explained by the modest gender difference in glioma. SE in general is more common among men, which has been explained by the higher male frequency of cerebrovascular disease [36] . However, our findings in a tumor population suggest that gender differences in epileptogenicity or other factors might be important.
More than 70% of the SE in this study was controlled by first or second line treatment, of which 75% had a well-controlled seizure situation prior to SE. About one fourth were treatment refractory, which is toward the lower margin of estimations reported for SE with other etiology than tumor [12] . Refractory SE has been estimated to 23-43% in different studies and is associated with high morbidity and mortality [37] [38] [39] [40] . SE associated with tumor progression was not less treatment responsive but had worse outcome, which could be due to SE, the tumor progression or both. Thus, evaluating outcome measures with respect to SE are uncertain in this subgroup. However, we hypothesize that SE in the context of tumor progression might exacerbate the neurological decline. We found a similar 30 days' mortality rate for HGG with SE as a previous study, 20% vs 18% [16] . Tumor progression was known in all cases that led to death within 3 months of SE except one. As SE is a medical emergency and progression may be unknown at the time of hospital admittance, we propose that all SE in glioma are treated aggressively until tumor status is clarified. In a setting of acknowledged tumor progression and RSE, the clinician may decide to withhold therapy requiring ICU -however, our data show that third line treatment is unnecessary in most cases. In addition, for palliative and psychological reasons, it is highly important to avoid SE in the terminal phase, and we suggest that effective SE therapy should not be withheld in any patient with clinical SE and glioma.
There were no losses to follow-up. Non-convulsive SE might be underdiagnosed in patients with marked consciousness impairment within the last weeks of life and dying at home or in nursing homes. The two neurological departments participating in the study covers the complete population in a defined geographical cohort. This material therefore has minimal selection bias, reflecting the total population of patients with a glioma and SE, recorded prospectively during 7 years.
Conclusion
Our results show that SE should be treated as aggressively in glioma patients as in patients with no tumor. The response to treatment was good and general anesthesia seldom required. SE arose in patients with clinically and radiologically stable disease as often as in patients with untreated tumor or tumor in progression. Patients with SE triggered by tumor progression were not more refractory to treatment than patients with a stable glioma.
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